Search research articles
Contact Us
Filters
Showing results (91-100 of 132) with videos related to
Page
of 14
Sort By:
Therapeutic Advances in Gastroenterology
|
August 22, 2020
Comparison of the effect of clarithromycin triple therapy with or without <i>N</i>-acetylcysteine in the eradication of <i>Helicobacter pylori</i>: a randomized controlled trial
Chieh-Chang Chen, Jiing-Chyuan Luo, Yu-Jen Fang, et al.
The Lancet. Gastroenterology & Hepatology
|
December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
Jyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Clinical and Molecular Hepatology
|
October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Lancet (London, England)
|
October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
The Lancet. Gastroenterology & Hepatology
|
February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Helicobacter
|
September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve Adults
Mei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C
Chun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 132) with videos related to
Sort By:
Page
of 14
Therapeutic Advances in Gastroenterology
|
August 22, 2020
Comparison of the effect of clarithromycin triple therapy with or without <i>N</i>-acetylcysteine in the eradication of <i>Helicobacter pylori</i>: a randomized controlled trial
Chieh-Chang Chen, Jiing-Chyuan Luo, Yu-Jen Fang, et al.
The Lancet. Gastroenterology & Hepatology
|
December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
Jyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Clinical and Molecular Hepatology
|
October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Lancet (London, England)
|
October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
The Lancet. Gastroenterology & Hepatology
|
February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Helicobacter
|
September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve Adults
Mei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C
Chun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Page
of 14